A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus

Recruiting · NCT07405970 · Interventional (participants receive a specific treatment) · Lead sponsor: Beijing Mabworks Biotech Co., Ltd.

Interventions studied

MIL62Placebo

This study will evaluate the efficacy and safety of MIL62 compared with placebo in participants with systemic lupus erythematosus.

Age range

18 Years to 80 Years

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Phase 3

Study type

Interventional (participants receive a specific treatment)

Age 18-80 ;
Diagnosis of systemic lupus erythematosus according to European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria ;
Positive antinuclear antibodies (ANA) ≥ 1:80 at screening or positive anti- dsDNA ;
High disease activity at screening ,SLEDAI-2000 score ≥8 (excluding alopecia score);
On a stable dose of one or more standard treatments for SLE prior to the first administration；
Able and willing to provide written informed consent and to comply with the study protocol.

Unsufficient organ function;
Received rituximab or any B-cell depleting drug within 9 months prior to the first dose;
Subjects with CD4+ T lymphocyte count \< 200 cells/μL;
Received cyclophosphamide within 8 weeks prior to the first dose; received calcineurin inhibitors (cyclosporine, tacrolimus, etc., except for topical use) or plasma exchange therapy within 4 weeks prior to the first dose;
Received a B-cell stimulating factor inhibitor such as Belimumab, and Telitacicept within 8 weeks prior to the first administration;
TNF inhibitor, interleukin monoclonal antibody, JAK inhibitor, BTK inhibitor, TYK2 inhibitor, or thalidomide within 4 weeks prior to the first administration;
Received live or attenuated vaccination within 28 days prior to the first administration;
Participated in other clinical trials within 28 days prior to the first administration;
Concomitant with other serious diseases;
Positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) with HBV DNA titer above the normal range; positive for hepatitis C virus (HCV) antibody; positive for human immunodeficiency virus (HIV);
Subjects with known history of severe allergic reactions to humanized monoclonal antibodies MIL62;
Breastfeeding or pregnant women;
Childbearing potential and unwillingness or impossibility to comply with a scientifically acceptable birth-control method;
Other conditions unsuitable for participation in this study determined by the Investigator.

1 location listed.